Alidornase alfa

Drug Profile

Alidornase alfa

Alternative Names: AIR DNAse™; PRX 110

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Protalix BioTherapeutics
  • Class Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 08 Feb 2017 Chemical structure information added
  • 03 Jan 2017 Interim efficacy data from a phase II trial in Cystic fibrosis released by Protalix BioTherapeutics
  • 22 Dec 2016 Protalix BioTherapeutics completes enrolment in its phase II trial for Cystic fibrosis in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top